BrainStorm Cell Therapeutics Inc (BCLI)

[Fmello]

BrainStorm Brings MS Data on Heels of ALS BLA Announcement (Updated)

https://www.biospace.com/article/brainstorm-brings-ms-data-on-heels-of-als-bla-submission-announcement-/

The study compared these 20 patients to 48 matched controls from the Comprehensive Longitudinal Investigation of Multiple Sclerosis (CLIMB) registry of Brigham and Women's Hospital and the Ann Romney Center for Neurologic Diseases. All comparison metrics fell strongly in NurOwn’s favor as the study met all endpoints.

NurOwn demonstrated “large, clinically meaningful improvements in some patients,” across measurements in all endpoints measured, BrainStorm reported.

In the first, 19% of participants treated with NurOwn responded with a 25% or greater improvement in the timed 25-foot walk speed (T25FW) or the 9-hole peg test (9HPT) at 28 weeks compared to baseline. This contrasted with 4% of the matched CLIMB controls.

In another endpoint, 67% of NurOwn-treated patients showed a 3-point or greater improvement in the symbol digit modality test (SDMT) compared to 18% of matched CLIMB registry patients.

Aside from the CLIMB registry, 38% of participants treated with NurOwn showed an improvement greater than or equal to 10-points from baseline in the multiple sclerosis walking scale (MSWS).

The company will also present additional data at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference in October.